Evidence map›Paper›PMID 24132657›Full record

ReviewAnnals of biomedical engineering2014

Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013.

Ying Wang, Linzhao Cheng, Sharon Gerecht

Abstract readReview
In one paragraph

Review in Annals of biomedical engineering, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Stem Cell Spheroids and Ex Vivo Niche Modeling: Rationalization and Scaling-Up.Journal of cardiovascular translational research · 2017
    Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ying WangDepartment of Chemical and Biomolecular Engineering and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 N. Charles St., Baltimore, MD, 21218, USA.
Linzhao Cheng
Sharon Gerecht

Funding

Functional Genomics of Platelet Aggregation Using iPS and Derived MegakaryocytesU01HL107446 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BECKER, LEWIS C, CHENG, LINZHAO · 2011 to 2015
$8.8M
Human embryonic stem (ES) and embroyonic germ (EG) cells to blood and immune cellR01HL073781 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHENG, LINZHAO · 2003 to 2013
$4.2M
NHLBI NIH HHS 2R01-HL073781NHLBI NIH HHS R01 HL073781NHLBI NIH HHS U01 HL107446NHLBI NIH HHS U01-HL107446
6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs) hold great promise for revolutionizing regenerative medicine for their potential applications in disease modeling, drug discovery, and cellular therapy. Many their applications require robust and scalable expansion of hPSCs, even under settings compliant to good clinical practices. Rapid evolution of media and substrates provided safer and more defined culture conditions for long-term expansion of undifferentiated hPSCs in either adhesion or suspension. With well-designed automatic systems or fully controlled bioreactors, production of a clinically relevant quantity of hPSCs could be achieved in the near future. The goal is to find a scalable, xeno-free, chemically defined, and economic culture system for clinical-grade expansion of hPSCs that complies the requirements of current good manufacturing practices. This review provides an updated overview of the current development and challenges on the way to accomplish this goal, including discussions on basic principles for bioprocess design, serum-free media, extracellular matric or synthesized substrate, microcarrier- or cell aggregate-based suspension culture, and scalability and practicality of equipment.

Indexed as

BioreactorsCell Culture TechniquesHumansPluripotent Stem CellsRegenerative Medicine

Identifiers

PMID24132657
PMCPMC4436032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.